whirling blurry lights

Life Sciences & Healthcare Innovation Hub

Our innovation hub for life sciences and healthcare is a demonstration of Cooley’s enduring commitment to the industry. It serves as a centralized point from which to access the insights and unparalleled experience of leading legal thinkers from across the firm and around the world.

How to Prepare for a Successful JPM Conference

The Cooley team discussed how to prepare for attending the JPM Healthcare Conference 2024 – including current industry trends and strategies for successful meetings with investors and partners. Attendees heard about how to make the most of your time at JPM from these trusted life sciences company advisers.

Tales From the 2022 Biotech VC Fundraising Trail

Cooley partner Josh Seidenfeld was quoted by the Wall Street Journal about biotech venture funding leading up to and throughout the year 2022.


Wall Street Journal • December 22, 2022

Life Sciences ESG Reporting Practices

For life sciences companies, ESG reporting is often a particularly perplexing subject. Investor focus on ESG matters is generally a more recent phenomenon for industry companies that also often are unsure which ESG topics are relevant to their business, especially earlier-stage companies. We have prepared this report to help life sciences companies begin to answer such questions and provide insight into industry disclosure practices.

November 14, 2022

2022 BIO International Convention

Cooley is proud to once again chair the digital health track at the BIO International Convention, which offers ample opportunities to connect with peers and others who can help you achieve your business goals. Cooley partners are among the global thought leaders addressing critical topics at the intersection of science, business and policy.

June 10, 2022

Staying Connected to Capital and Investors

“In Cooley’s Q4 2021 Venture Financing Report, the firm reported that it handled 82 disclosable financings of life sciences companies, representing more than $5.2 billion of invested capital. Deal sizes spiked, with an average deal size of more than $63 million in the quarter. Meanwhile, in a signal of investor caution, the percentage of life sciences transactions structured in tranches increased to more than 17% of deals, doubling from the prior quarter.”

California Life Sciences Bulletin: Medtech Spotlight • March 11, 2022

Medtech Primer on the FDA Regulatory Landscape

“Medtech companies are subject to FDA regulation as medical device manufacturers if their products satisfy the ‘device’ definition in the Federal Food, Drug and Cosmetic Act (FDCA). As that definition explains, if a product is intended to diagnose, cure, mitigate, treat or prevent a disease, or is intended to affect the structure or any function of the body, it is regulated by FDA as either a drug or a device. If the product achieves its primary intended purpose through chemical or metabolic means, it is a drug; all other such medical products are devices under the FDCA.”

California Life Sciences Bulletin: Medtech Spotlight • March 11, 2022

Q1 2022 Venture Financing Report – Deal Volume Remains High, Varies by Industry

Cooley continued to represent a near-record number of emerging companies and venture investors in disclosable VC financings during the first quarter of 2022.

May 11, 2022